CIENCIASMEDICASNEWS

miércoles, 25 de marzo de 2026

CLINICAL PERSPECTIVES: MajesTEC-9 Clinical Trial of Teclistamab in Patients With Multiple Myeloma +++ +++ +++

CLINICAL PERSPECTIVES MajesTEC-9 Clinical Trial of Teclistamab in Patients With Multiple Myeloma https://checkrare.com/majestec-9-clinical-trial-of-teclistamab-in-patients-with-multiple-myeloma/ Roberto Mina, MD, Associate Professor at Winship Cancer Institute of Emory University, discusses the Majestec-9 clinical trial of Tecvayli (teclistamab) in patients with multiple myeloma (MM). Using Artificial Intelligence to Analyze Castleman Disease Histopathology https://checkrare.com/using-artificial-intelligence-to-analyze-castleman-disease-histopathology/ Robert S. Ohgami, MD, PhD, Professor of Pathology, University of Utah, and Founding Vice President and Chief Medical Director, ARUP Institute for Research and Innovation, discusses the utilization of artificial intelligence (AI) to analyze Castleman disease (CD) histopathology. Elritercept’s Effect on Transfusion Independence in Patients With Myelodysplastic Syndromes https://checkrare.com/elritercepts-effect-on-transfusion-independence-in-patients-with-myelodysplastic-syndromes/ Lynette Chee, PhD, Hematologist at The Royal Melbourne Hospital/ Peter MacCallum Cancer Centre, discusses elritercept’s effect on transfusion independence (TI) in patients with myelodysplastic syndromes. 52-Week Results From the VERIFY Clinical Trial of Rusfertide in Patients With Polycythemia Vera https://checkrare.com/52-week-results-from-the-verify-clinical-trial-of-rusfertide-in-patients-with-polycythemia-vera/ Andrew T. Kuykendall, MD, VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center, discusses 52-week results from the VERIFY clinical trial testing rusfertide in patients with polycythemia vera (PV). Bleximenib Combination Therapy for Patients With Acute Myeloid Leukemia https://checkrare.com/bleximenib-combination-therapy-for-patients-with-acute-myeloid-leukemia/ Hartmut Döhner, MD, Professor of Medicine and Medical Director of the Department of Hematology and Oncology, Ulm University, Germany, discusses bleximenib combination therapy for treatment of patients with acute myeloid leukemia (AML). A Family’s Experience With Nasopharyngeal Carcinoma https://checkrare.com/a-familys-experience-with-nasopharyngeal-carcinoma/ Floyd Stewart, patient with stage 4 nasopharyngeal carcinoma, and Monique Stewart, advocate and Floyd’s wife, discuss their family’s experience with the disease and their advocacy work. Treatment With Elritercept for Patients With Myelofibrosis https://checkrare.com/treatment-with-elritercept-for-patients-with-myelofibrosis/ Ciro Rinaldi, MD, Consultant Hematologist and Professor of Hematology at United Lincolnshire Hospital, discusses treatment with elritercept for patients with myelofibrosis (MF). Updated Phase 2 Results of Telquetamab + Teclistamab in Multiple Myeloma https://checkrare.com/updated-phase-2-results-of-telquetamab-teclistamab-in-multiple-myeloma/ Saad Usmani, MD, Myeloma Specialist and Cellular Therapist at Memorial Sloan Kettering Cancer Center, discusses updated results from the phase 2 RedirecTT-1 study of telquetamab + teclistamab in patients with multiple myeloma (MM). Results from the CARTITUDE-4 Clinical Trial in Multiple Myeloma https://checkrare.com/results-from-the-cartitude-4-clinical-trial-in-multiple-myeloma/ Binod Dhakal, MD, Associate Professor of Medicine at Medical College of Wisconsin, discusses results from the CARTITUDE-4 clinical trial in patients with multiple myeloma (MM).

Bringing RNA therapies full circle with transient CAR T A new in vivo approach programs patients’ T cells directly, bypassing complex manufacturing and expanding access to CAR T therapies.

https://www.drugdiscoverynews.com/bringing-rna-therapies-full-circle-with-transient-car-t-17082 Chimeric antigen receptor (CAR) T cell therapies have transformed treatment paradigms in oncology and are now showing promise in autoimmune diseases. But despite their clinical impact, today’s approved CAR T therapies remain constrained by a complex, ex vivo manufacturing model. T cells must be harvested from each patient, genetically engineered outside the body, expanded, and reinfused — an approach that is costly, time-intensive, and available only at highly specialized centers.

New spinal fluid biomarker distinguishes Parkinson's and Lewy body dementia from Alzheimer's disease Immunoassays measuring DOPA decarboxylase in cerebrospinal fluid achieve high diagnostic accuracy.

https://www.drugdiscoverynews.com/new-spinal-fluid-biomarker-distinguishes-parkinson-s-and-lewy-body-dementia-from-alzheimer-s-disease-17091 Diagnosing dementia with Lewy bodies (DLB) has long been one of neurology's more stubborn problems. The condition shares significant symptom overlap with Alzheimer's disease (AD) and other dementias, and misdiagnosis is common — with real consequences, since treatments effective for one condition can be harmful in another. A new study published in Nature Medicine may change that.

Bullous Pemphigoid in Focus: A Live Think-Pair-Share Workshop Authors: Ruth Ann Vleugels, MD, MPH, MBA; Kyle T. Amber, MD, FAAD; Karl Saardi, MD

https://www.medscape.org/viewarticle/bullous-pemphigoid-focus-live-think-pair-share-workshop-2025a1000tfu?page=1&src=mkmcmr_driv_stan_mscpedu_260324-OUS-HONC-bullous-pemphigoid-focus-live-think-pair-share-workshop-2025a1000tfu-cta&uac=148436CN

Improving mCRPC Outcomes Using Radiopharmaceuticals: Evidence to Implementation Authors: Rana R. McKay, MD, FASCO; Matthew R. Cooperberg, MD, MPH; Sean M. McBride, MD, MPH, MS

https://www.medscape.org/viewarticle/1003039?uac=148436CN&src=mkmcmr_driv_stan_mscpedu_260324-OUS-HONC-1003039-cta

2025 Provisional TB Data Report Release +... +++ +++

https://www.cdc.gov/nchhstp/director-letters/2025-provisional-tb-data.html?ACSTrackingID=DM153610&ACSTrackingLabel=%20CDC%20Releases%20Preliminary%20TB%20Data%20on%20World%20TB%20Day&deliveryName=DM153610 On March 24, we recognize World TB Day. This annual event commemorates the date Dr. Robert Koch announced his discovery of the bacillus that causes tuberculosis (TB). https://www.cdc.gov/world-tb-day/index.html?ACSTrackingID=USCDC_18_1-DM143079&ACSTrackingLabel=World%20TB%20Day&deliveryName=USCDC_18_1-DM143079 Today, CDC is releasing the 2025 Provisional Tuberculosis (TB) Data Report , which shows that TB cases in the United States remained elevated over pre-pandemic levels, with a slight decrease (1%) in cases compared to 2024. There were 10,260 cases provisionally reported in 2025, compared to 10,395 cases in 2024. The rate of TB was 3.0 cases per 100,000 people in 2025 compared to 3.1 cases per 100,000 in 2024, a 2% decrease. It is important to note that these data are preliminary and may change when final numbers are published later this year. Eliminating TB in the United States requires a dual approach that prioritizes addressing both active TB disease to stop TB transmission and latent TB infection (LTBI) to prevent future disease. This includes promptly diagnosing and treating people with TB disease and medically evaluating and treating their close contacts, and increasing efforts to test and treat LTBI among populations at risk. To accelerate progress toward TB elimination, it is vital that we expand our dual approach and continue to engage communities with higher TB rates and their medical providers in TB elimination efforts. We must ensure that state and local TB programs across the country are equipped to carry out routine TB prevention and elimination activities, respond quickly to cases, and stop outbreaks. Tuberculosis is preventable and treatable, yet it remains the world's deadliest infectious disease. The United States continues to maintain one of the lowest TB incidence rates globally, and transmission remains uncommon — reflecting the strength of our national, state, and local TB programs. We gratefully acknowledge the contributions of all state and local health departments throughout the United States. Their staff collected and reported the information used in the provisional TB data report to help direct public health efforts. CDC's World TB Day digital toolkit includes graphics and videos to help spread the message to think, test, and treat TB. https://www.cdc.gov/think-test-treat-tb/index.html?ACSTrackingID=USCDC_18_1-DM143079&ACSTrackingLabel=World%20TB%20Day&deliveryName=USCDC_18_1-DM143079 Thank you for your continued partnership, work, and commitment to eliminating TB in the United States. Sincerely, Deron Burton, MD, JD, MPH CAPT, USPHS Director, Division of Tuberculosis Elimination National Center for HIV, Viral Hepatitis, STD, and TB Prevention U.S. Centers for Disease Control and Prevention https://www.cdc.gov/world-tb-day/communication-resources/videos.html?ACSTrackingID=USCDC_18_1-DM143079&ACSTrackingLabel=World%20TB%20Day&deliveryName=USCDC_18_1-DM143079 https://www.cdc.gov/world-tb-day/communication-resources/index.html?ACSTrackingID=USCDC_18_1-DM143079&ACSTrackingLabel=World%20TB%20Day&deliveryName=USCDC_18_1-DM143079 https://www.cdc.gov/world-tb-day/communication-resources/index.html?ACSTrackingID=USCDC_18_1-DM143079&ACSTrackingLabel=World%20TB%20Day&deliveryName=USCDC_18_1-DM143079 https://www.cdc.gov/tb-data/aboutprovisionaldata/2025-provisional-data.html